NovoTTF-100A FDA Approved

The FDA approved the NovoTTF-100A today. This is Novocure's head device that uses alternating electric fields that enter the brain through electrodes to kill cancer cells. Kent was one of the 237 patients in the pivotal clinical trial for this treatment. It didn't work for him but it has worked for a lot of other GBM IV patients, so this is great news in the brain tumor community.

Brain Tumor Action Week

This week is Brain Tumor Action Week in Washington, DC which is a joint effort in the brain tumor community of patients and their families, friends and health care providers along with the North American Brain Tumor Coalition to educate the public about brain tumors.

Despite the efforts of some of the world’s finest researchers to develop better therapies for brain tumors, individuals who are diagnosed with them still do not have adequate treatment choices. In fact, the outlook for brain tumor patients has not improved that much in the last 20 years.

With this in mind, tomorrow, May 4th, is Advocacy Education Day which means the NABTC will be advocating Congress to take action on important issues to better serve the brain tumor community.

We can support Brain Tumor Action Week and National Brain Tumor Awareness Month by contacting our state Senators and Representatives as well as wearing gray ribbon t-shirts, hats, wristbands, etc.